Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2024 09:15 ET | Source: Fibrobiologics, Inc.

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology

HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
October 28, 2024 09:31 ET | Source: Fibrobiologics, Inc.

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
October 18, 2024 08:30 ET | Source: Fibrobiologics, Inc.

FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases

HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, development,...
October 16, 2024 09:15 ET | Source: Fibrobiologics, Inc.

FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office

HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
October 11, 2024 09:31 ET | Source: Fibrobiologics, Inc.

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
September 30, 2024 09:31 ET | Source: Fibrobiologics, Inc.

FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa

HOUSTON, Sept. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
September 19, 2024 09:31 ET | Source: Fibrobiologics, Inc.

FibroBiologics Engages Southern Star Research as CRO in Australia

HOUSTON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
September 12, 2024 09:31 ET | Source: Fibrobiologics, Inc.

FibroBiologics Announces Filing of Patent Application for Generation of Functional Hematopoietic Organoids using Fibroblast Cell-Based Technology

HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
September 06, 2024 09:31 ET | Source: Fibrobiologics, Inc.

FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

HOUSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
August 20, 2024 09:31 ET | Source: Fibrobiologics, Inc.

FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology

HOUSTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right